Online inquiry

IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9167MR)

This product GTTS-WQ9167MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD37 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001040031.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 951
UniProt ID P11049
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ9167MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15262MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ14069MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-3918
GTTS-WQ12787MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ15360MR IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA TRC-105
GTTS-WQ5418MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CD74-DOX (ADC)
GTTS-WQ15382MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA TRU-016
GTTS-WQ2750MR IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG162
GTTS-WQ7922MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA GSK3196165
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW